Molecular Arsonists: Degrading Oncogenic Transcription Factors to Reverse Tumor Cell Immortality
ISEF · 2025 Biomedical and Health Sciences
Overview
Glioblastoma (GBM) is the most predominant malignant brain cancer in adults without prognosis improvement in decades. Nevertheless, 83% of GBM cases have Telomerase Reverse Transcriptase promoter (TERTp) mutations, enabling the GA-binding protein (GABP) transcription factor complex to bind and reactivate TERT expression, allowing the tumor to divide indefinitely. While directly targeting telomerase has systemic toxicity, targeting GABP may allow tumor-specific TERT silencing. Because targeting transcription factors with small-molecule inhibitors is nearly impossible, a novel approach is required. Last year, a GABPB1 dominant negative was designed, reducing TERT expression in glioma cells. Still, because GABPB has multiple isoforms, it could reactivate TERT. To improve this approach, a strategy for creating biologic-based Proteolysis-Targeting Chimeras (bioPROTACs) was devised to target GABP. Using GABPA, the binding partner of GABPB isoforms, we engineered a GABPA dominant-negative by mutating key DNA-binding residues. AlphaFold3.0 was then utilized to identify the smallest GABPA capable of binding to GABPB1/2 via in-silico modeling. Finally, this minimal GABPA-DN was functionalized by attaching a Ubiquitin degrader (SPOP) or a lysosomal degrader (CMA) domain, resulting in an 80-90% decrease in TERT expression and a near-complete degradation of all GABPB1 isoforms in tumor cells. Here, I present a strategy for the creation of biologic-based therapeutics targeting oncogenic transcription factors utilizing modern machine learning algorithms, using the master regulator of mutant TERT promoter-driven tumor immortality as a proof-of-concept, providing a powerful example for the potential applications it may have in other transcription factor-regulated diseases.
Competition history
- ISEF 2025
Resources
Related projects
ISEF · 2026
Protein Assassins: Screening for Improved Degraders to Reverse Tumor Immortality
ISEF · 2024
Grand Theft Transcription Factor: Reversing Tumor Cell Immortality by Transcription Factor Relocalization
ISEF · 2023
Novel Strategies for the Reversal of Cancer Cell Immortality
JSHS · 2025
Molecular Arsonists: Degrading Oncogenic Transcription Factors to Reverse Tumor Immortality
JSHS · 2024
Grand Theft Transcription Factor: Reversing Tumor Cell Immortality by Transcription Factor Relocalization
ISEF · 2026
GCORE: Glioblastoma-Related Chimeric Antigen Receptor T Cell Therapy Outcome Re-Engineering
ISEF · 2025
TETRA-C: Accelerating Cancer Therapy Through AI-Optimized Telomerase Inhibition, Enzymatic Targeting, and the Suppression of Metastasis
ISEF · 2026
Targeting Pathological Neurotransmission Dynamics Through de novo Regulatory Modulation to Suppress Glioma Progression
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair